Coronavirus Update: Veklury Shows Mortality Benefit In Real-World Data Analyses

Vir/GSK Announce Positive Phase III Data For Sotrovimab

Sotrovimab data could help with uptake, though the market remains challenging as infections fall. Plus RedHill presents encouraging Phase II data for oral drug to treat COVID-19 infection and inflammation after completing Phase II/III study enrollment and Japan taps its world-leading supercomputer.

It remains uncertain how long Gilead Sciences, Inc.’s COVID-19 antiviral Veklury (remdesivir) will be a significant source of sales as infection rates fall in the US, vaccination rates increase and more drugs become available, but a new cache of real-world data showing a mortality benefit could help the drug retain its role as a standard of care.

Gilead is presenting data at the World Microbe Forum, running 20-24 June, from three analyses of real-world datasets that it...